The biotech company Curevac is starting a new clinical phase 2a study for the COVID-19 vaccine candidate CVnCoV in Panama and Peru. The study is designed as a dose confirmation study and should, according to company information from Wednesday night, “include a total of 690 healthy participants in two different groups: older adults aged 61 and over and younger participants between 18 and 60 years old”. The basis is the immunogenicity data from CureVac’s ongoing phase 1 study with the COVID-19 vaccine candidate.
“In anticipation of further data from the ongoing phase 1 study and the phase 2a study, CureVac plans to start the global clinical phase 2b / 3 study with up to 30,000 participants in the fourth quarter of 2020,” said the Tübingen-based biotech Company whose vaccine candidate is considered to be one of the various important projects in the fight against the global corona pandemic. The study in Panama and Peru should confirm the dose selection for the vaccine candidate and also provide further safety data for the vaccine, especially in the elderly.
On the NASDAQ, the Curevac share ended yesterday’s trading at 45.68 euros, slightly in the red. However, today’s reaction to the news from Wednesday night could be interesting after the stock market rookie had dropped from the top at $ 85 to as low as $ 43.00 in the past few weeks. An upward trend reversal seems possible, but is dependent on further technical buy signals. We had this in one yesterday 4investors chart check on the Curevac share already discussed. At the technical chart resistance level at 47.21 / 48.01 dollars, this potential trend signal will then be decided.